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A B S T R A C T
Social cognition includes a range of cognitive processes that help individuals to understand how others think and
feel. There is emerging evidence that social cognitive deﬁcits may represent a transdiagnostic issue, potentially
serving as a marker of neurological abnormality. We performed an electronic database search in order to identify
published, peer-reviewed meta-analyses that compared facial emotion recognition or theory of mind task per-
formance between individuals meeting clinical criteria for a psychiatric, neurological or developmental condi-
tion against healthy controls. We identiﬁed 31 meta-analyses eligible for inclusion that examined performance
across relevant tasks among 30 diﬀerent clinical populations. The results suggest that social cognitive deﬁcits
appear to be a core cognitive phenotype of many clinical conditions. Across the clinical groups, deﬁcits in social
cognitive domains were broadly similar in magnitude to those previously reported for more established aspects
of cognition, such as memory and executive function. There is a need to clarify the ‘real world’ impact of these
deﬁcits, and to develop eﬀective transdiagnostic interventions for those individuals that are adversely aﬀected.
1. Introduction
Social cognition refers to the ‘mental operations that underlie social
interactions’ and includes a range of cognitive processes that help in-
dividuals to understand how others think and feel (Frith, 2008; Green
et al., 2008). The most heavily researched aspects of social cognition
are emotion recognition and theory of mind (ToM); two partially
overlapping but distinct cognitive domains (Mitchell and Phillips,
2015). Emotion recognition refers to an individual’s ability to identify
and discriminate between the basic emotional states of others, typically
based on their facial or vocal expressions. Theory of mind refers to the
ability to infer more complex mental states, including the intentions,
dispositions, and beliefs of others, and is thought to comprise distin-
guishable but overlapping cognitive and aﬀective components (Green
et al., 2015; Poletti et al., 2012). Collectively these drive interpersonal
skills such as empathy, and are thought to be important for ﬂuid
communication and social interaction.
The neural basis of social cognitive processing is complex, involving
a range of cortical and subcortical regions and connective pathways
(Van Overwalle, 2009). This ‘social brain’ network varies depending on
task demands, but is broadly thought to include limbic regions (such as
the amygdala), the prefrontal cortex and temporoparietal junction, as
well as the anterior cingulate and insular cortex (Forbes and Grafman,
2010; Lavin et al., 2013; Lindquist et al., 2012; Molenberghs et al.,
2016). Many of these regions are adversely aﬀected in people with
neurological or psychiatric conditions (Batista et al., 2017a, 2017b;
Cusi et al., 2012; Patriquin et al., 2016; Seeley et al., 2009), suggesting
social cognitive dysfunction may be common across these populations.
Pioneering early work in this ﬁeld focused on the central role of
ToM impairments as a hallmark feature of autism spectrum disorders
(Baron-Cohen et al., 1985; Happé and Frith, 1996). Subsequently,
deﬁcits in both emotion recognition and ToM have been identiﬁed as
core cognitive deﬁcits in schizophrenia (Savla et al., 2013; Kohler et al.,
2010), and have been reported to be among the strongest predictors of
impaired social functioning in this population (Fett et al., 2011;
Galderisi et al., 2014; Green, 2016). There is also preliminary evidence
that deﬁcits in social cognitive processes may contribute to deteriora-
tion in psychosocial functioning in other clinical groups (Aydemir et al.,
2013; Phillips et al., 2011; Trevisan and Birmingham, 2016). More re-
cently, some aspects of emotion recognition have also been proposed to
play a causal role in the onset and maintenance of a range of mental
health conditions (Penton-Voak et al., 2017). As a result, investigation
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of social cognitive dysfunction has become an emerging area of interest
across a range of developmental, psychiatric and neurological disorders
(Bora and Pantelis, 2016; Cotter et al., 2016; Plana et al., 2014).
Despite recent calls emphasising its importance (Henry et al., 2016),
social cognitive assessment has been largely overlooked clinically to
date. This could have the potential to serve as a marker of neural de-
terioration and disease progression, particularly for neurodegenerative
conditions, as well as treatment response. There has also been little
consideration of these deﬁcits as a transdiagnostic issue. Social cogni-
tive deﬁcits potentially represent an under recognised domain of im-
pairment across disorders, with both functional and clinical relevance.
In this review, we sought to collate existing meta-analytic data on social
cognitive performance among individuals with a range of clinical
conditions.
2. Method
This review was conducted in line with the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines
(Moher et al., 2009).
2.1. Study inclusion criteria
Eligible articles were meta-analyses published in peer-reviewed
journals that examined the diﬀerence in performance on facial emotion
recognition or ToM tasks between individuals with a clinically diag-
nosed psychiatric, neurological or developmental condition and healthy
controls. Facial emotion recognition eﬀect size estimates were required
to have been derived from tasks in which participants had to identify,
label or match images of faces consisting of all or any combination of
the six basic emotions (happiness, sadness, anger, fear, surprise or
disgust) (Ekman and Friesen, 1976). Where possible, a ‘total’ score was
used, comprising performance across multiple emotions. ToM or
‘mentalizing’ tasks required the identiﬁcation or interpretation of more
complex mental states and/or beliefs (such as lies, jokes, sarcasm or
faux pas).
Standardised mean diﬀerence eﬀect size estimates (Cohen’s d or
Hedges’ g) must have been derived from two or more independent
studies in order for the meta-analysis to be included. Where data was
reported for diﬀerent states of a given condition (e.g. remitted/acute
symptoms), we included the overall ‘pooled’ estimates from across
those states when available. Where there were multiple publications for
a given medical condition that met our inclusion criteria, we included
the most recently published paper. Meta-analyses of interventions were
ineligible. No language restrictions were placed on studies for inclusion.
2.2. Search strategy
On 1st May 2017, we conducted an electronic database search of
Ovid MEDLINE, PsycINFO, Embase and the Cochrane Database of
Systematic Reviews (from inception) using the following keyword
search terms: “social cogniti*” or “theory of mind” or “mentalizing” or
“emotion” and “meta-analysis”. In addition; a search of Google Scholar
was conducted and the reference lists of retrieved articles were also
reviewed to identify any additional relevant publications. An additional
eligible meta-analysis that was published following the formal search
date was also later identiﬁed and included.
2.3. Study selection and data extraction
Three of the authors (J.C., R.B. and M.H.) independently screened
articles for eligibility. A standardised data extraction spreadsheet was
used for all eligible studies to record: (1) study characteristics (authors,
year of publication, clinical condition(s) examined); (2) social cognitive
domains assessed (facial emotion recognition and/or ToM); (3) sample
characteristics (the number of studies and the sample sizes for the
clinical and control groups included for each of the summary esti-
mates); (4) social cognitive performance in the clinical relative to
control group (eﬀect size, eﬀect size metric and associated 95% con-
ﬁdence intervals).
Eﬀect sizes generated using either Cohen’s d or Hedges’ g were in-
cluded. These represent the diﬀerence between the clinical and control
group means, divided by the pooled standard deviation and weighted
for sample size. Hedges’ g includes an additional correction for small
sample size bias, but is broadly comparable to Cohen’s d (Lakens,
2013). Eﬀect sizes generated using either approach are typically in-
terpreted as representing small (≤0.2), medium (0.5), or large (≥0.8)
group diﬀerences based on these methods (Cohen, 1988). Scores were
re-coded where necessary so that negative eﬀect size estimates always
reﬂected poorer performance in the clinical group relative to controls.
Where data was reported from both ﬁxed and random eﬀects models,
we included the results from the random eﬀects analyses. These models
provide more conservative estimates by accounting for observed het-
erogeneity. Where reported, we also recorded the degree of hetero-
geneity within eﬀect size estimates (I2 statistic), as well as any tests that
were performed to detect evidence of potential publication bias (Egger’s
test, Begg’s test and/or the Fail-safe N). Eﬀect size estimates were
classiﬁed as having a ‘low risk’ or ‘possible risk’ of publication bias
based on the results of these analyses.
3. Results
The study selection process is summarised in Fig. 1. We identiﬁed
31 meta-analyses eligible for inclusion that examined performance on
facial emotion recognition (24 papers) and/or ToM tasks (24 papers)
among 30 diﬀerent clinical populations relative to controls (Table 1).
Across clinical conditions, the facial emotion recognition and ToM ef-
fect size estimates each collectively included data acquired from around
20,000 clinical and control participants. Though the eﬀect sizes are not
directly comparable across clinical conditions (due to methodological
diﬀerences between studies and in meta-analytic procedures), they
demonstrate consistent and statistically signiﬁcant deﬁcits in facial
emotion recognition and ToM across almost all of the clinical groups
included in this review (Figs. 2 and 3). These also provide an indication
of the magnitude of these diﬃculties. Within speciﬁc conditions, the
severity of deﬁcits in facial emotion recognition and ToM task perfor-
mance were broadly comparable with one another, suggesting patients
with particular disorders have similar levels of diﬃculty across each of
these social cognitive domains. Among individuals with neurological or
developmental disorders, deﬁcits across both task types were in the
medium-to-large range (−0.41 to−1.81). Individuals with psychiatric
disorders exhibited wider variation in the severity of these deﬁcits,
potentially due to greater variability in disease state and severity.
Perhaps unsurprisingly, the greatest impairments were observed in
patients with neurodegenerative disorders, though large deﬁcits were
also observed in people with psychotic disorders.
Heterogeneity was evident in the eﬀect size estimates and ranged
from low to high. There was a possible risk of publication bias asso-
ciated with 7 of the 34 eﬀect size estimates that included tests for
publication bias, suggesting overall that these results provide a robust
indication that social cognitive deﬁcits are common across many of the
included clinical populations.
4. Discussion
4.1. Overview of ﬁndings
In summary, we identiﬁed signiﬁcant deﬁcits among individuals
with a wide range of clinical conditions in their ability to identify
emotions from facial expressions and to successfully complete ToM
tasks, compared to healthy controls. Though these results do not pro-
vide directly comparable estimates between clinical conditions, they
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provide a robust indication that social cognitive deﬁcits appear to be a
core cognitive phenotype of many developmental, neurological and
psychiatric disorders.
4.2. Social cognition as a clinical marker
Across many conditions, deﬁcits in social cognitive domains were
broadly similar in magnitude to those previously reported on more
established aspects of cognition, such as memory, processing speed and
executive function (e.g. Beeldman et al., 2016; Demetriou et al., 2017;
Fioravanti et al., 2012; Prakash et al., 2008). The distinction between
neurocognitive and social cognitive processing remains an area of on-
going investigation. Though social cognitive deﬁcits are likely to be
exacerbated as a secondary deﬁcit to more general cognitive impair-
ments (for example, on tasks requiring rapid processing or a memory
component), there is evidence that these are dissociable cognitive
constructs. For example, neuroimaging studies suggest that these do-
mains rely on diﬀerent (though partially overlapping) neural systems,
while analysis of performance on social and neurocognitive tasks de-
monstrate that these also form diﬀerent factors (Bertoux et al., 2016;
Mehta et al., 2013; Van Overwalle, 2009). Studies have also indicated
that social cognitive dysfunction is exhibited by patients with otherwise
intact cognitive and perceptual performance (Cotter et al., 2016;
Fanning et al., 2012; Lagravinese et al., 2017). Given that these neu-
rocognitive deﬁcits are a target for therapeutic intervention in many
disorders, the magnitude of social cognitive deﬁcits should also be
considered clinically meaningful.
Social cognitive impairment has been posited as a potential marker
for autism and schizophrenia (Derntl and Habel, 2011). However, the
ﬁndings of this review suggest it may serve as a general biomarker
indicative of neurological abnormality across a range of clinical con-
ditions and warrants further attention. The results from this review
suggest that social cognitive measures should be integrated into large-
scale, longitudinal projects (alongside existing neurocognitive mea-
sures) using repeated assessments in order to examine their potential to
serve as longitudinal predictors of clinical and functional outcomes.
There is emerging evidence that social cognitive performance may
serve as a useful screening tool among individuals with neurodegen-
erative conditions. The presence of social cognitive deﬁcits in pre-
manifest Huntington’s disease have been reported to indicate a sig-
niﬁcantly higher risk of developing motor symptoms in the following 5
years (Bora et al., 2016b). Social cognitive screening also has the po-
tential to help improve early diagnosis between diﬀerent forms of
cortical dementias (Bertoux and Hornberger, 2015). Individuals with
behavioural-variant frontotemporal dementia exhibited signiﬁcantly
poorer performance across both facial emotion recognition and ToM
tasks compared to those with Alzheimer’s disease, despite worse
Mini–Mental State Examination performance in the Alzheimer’s group
(Bora et al., 2016a, 2015a). Eﬀect size diﬀerences across these measures
were much larger than those previously reported across more tradi-
tional neurocognitive tasks (Hutchinson and Mathias, 2007). This
suggests that social cognitive measures may be useful for identifying
which individuals are in the early stages of, or at risk of developing
behavioural-variant frontotemporal dementia compared to Alzheimer’s
disease, particularly among patients with mild cognitive impairment.
As well as being a potential marker for disease onset, social cogni-
tive assessment also appears to oﬀer the potential to examine disease
progression. There was evidence that social cognitive deﬁcits were
evident even among individuals in the early stages of a number of
conditions, with only mild levels of disease severity (Bora, 2017; Bora
et al., 2015b; Cotter et al., 2016; van Donkersgoed et al., 2015), but also
that they were more severe in those individuals with neurological
conditions with a longer disease duration (Bora et al., 2016b, 2015a),
and those with psychiatric disorders experiencing an exacerbation in
symptom severity (Bora et al., 2016c; Bora and Berk, 2016; Bora and
Köse, 2016).
Fig. 1. PRISMA ﬂow diagram.
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Table 1
Overview of included meta-analyses.
Condition Reference Domains
assessed
Studies
included
Sample n Eﬀect size
(95% CI)
Eﬀect size
metric
Heterogeneity (I2) Publication bias
Psychiatric disorders
At-risk mental state van Donkersgoed
et al. (2015)
FER 10 Clinical 444 −0.48 (−0.69,
−0.27)
Cohen’s d N/R N/R
Controls 375
ToM 7 Clinical 348 −0.44 (−0.68,
−0.19)
Cohen’s d N/R N/R
Controls 267
First-episode psychosis Barkl et al. (2014) FER 11 Clinical 378 −0.88 (−1.42,
−0.32)
Cohen’s d N/R N/R
Controls 369
Bora and Pantelis
(2013)
ToM 8 Clinical 285 −1.00 (−1.18,
−0.81)
Cohen’s d 0% Low risk
Controls 228
Schizophrenia Kohler et al. (2010) FER 53 Clinical 3822 −0.91 (−0.97,
−0.84)
Cohen’s d N/R Possible risk
Controls
Savla et al. (2013) ToM 50 Clinical 1760 −0.96 (−1.09,
−0.83)
Hedges’ g 66.50% Possible risk
Controls 1536
Bipolar disorder Kohler et al. (2011) FER 31 Clinical N/R −0.46 (−0.63,
−0.29)
Cohen’s d N/R N/R
Controls N/R
Bora et al. (2016c) ToM 34 Clinical 1214 −0.63 (−0.74,
−0.52)
Cohen’s d 36.50% Possible risk
Controls 1097
Major depressive disorder Dalili et al. (2015) FER 22 Clinical 977 −0.16 (−0.25,
−0.07)
Hedges’ g 0% Possible risk
Controls 843
Bora and Berk (2016) ToM 18 Clinical 613 −0.58 (−0.84,
−0.33)
Cohen’s d 74.80% Low risk
Controls 529
Borderline personality disorder Daros et al. (2013) FER 10 Clinical 266 −0.45 (−0.80,
−0.09)
Cohen’s d N/R Low risk
Controls 255
Richman and Unoka
(2015)
ToM 5 Clinical 224 −0.06 (−0.26,
0.13)
Cohen’s d N/R N/R
Controls 186
Generalised anxiety disorder Plana et al. (2014) FER 2 Clinical 58 −0.12 (N/R) Cohen’s d N/R N/R
Controls 48
Obsessive-compulsive disorder Plana et al. (2014) FER 12 Clinical 313 −0.16 (N/R) Cohen's d N/R N/R
Controls 357
ToM 2 Clinical 55 −0.30 (N/R) Cohen’s d N/R N/R
Controls 55
Panic disorder Plana et al. (2014) FER 2 Clinical 73 −0.25 (N/R) Cohen’s d N/R N/R
Controls 79
Social phobia Plana et al. (2014) FER 10 Clinical 217 −0.20 (N/R) Cohen’s d N/R N/R
Controls 239
Post-traumatic stress disorder Plana et al. (2014) FER 4 Clinical 68 −1.60 (N/R) Cohen’s d N/R N/R
Controls 63
Anorexia Nervosa Caglar-Nazali et al.
(2014)
FER 5 Clinical 185 −0.32 (−0.55,
−0.09)
Cohen’s d N/R Low risk
Controls 188
Bora and Köse (2016) ToM 14 Clinical 450 −0.59 (−0.81,
−0.37)
Cohen’s d N/R N/R
Controls 441
Bulimia Nervosa Caglar-Nazali et al.
(2014)
FER 2 Clinical 51 0.01 (−0.33,
0.36)
Cohen’s d N/R Low risk
Controls 98
Bora and Köse (2016) ToM 8 Clinical 227 −0.34 (−0.58,
−0.09)
Cohen’s d 45.31% N/R
Controls 267
Alcohol use disorder Bora and Zorlu (2017) FER 12 Clinical 410 −0.65 (−0.89,
−0.42)
Cohen’s d 60.18% Low risk
Controls 352
ToM 12 Clinical 317 −0.58 (−0.81,
−0.36)
Cohen’s d 44.55% Low risk
Controls 298
Substance use disorder (non-
alcohol)
Castellano et al.
(2015)
FER 10 Clinical 438 −0.65 (−0.93,
−0.37)
Cohen’s d 72.50% Low risk
Controls 422
Neurological disorders
Alzheimer’s disease Bora et al. (2015a) ToM 20 Clinical 402 −1.15 (−1.52,
−0.79)
Cohen’s d N/R Low risk
Controls 421
Amyotrophic lateral sclerosis Bora (2017) FER 5 Clinical 92 −0.69 (−0.97,
−0.42)
Cohen’s d 0% Low risk
Controls 152
ToM 11 Clinical 311 −0.65 (−0.84,
−0.47)
Cohen’s d 21% Possible risk
Controls 339
Behavioural variant
frontotemporal dementia
Bora et al. (2016a) FER 13 Clinical 237 −1.81 (−2.28,
−1.35)
Cohen’s d 80.7% Low risk
Controls 339
Bora et al. (2015a) ToM 20 Clinical 334 −1.79 (−2.18,
−1.40)
Cohen’s d N/R Low risk
Controls 391
Frontal lobe epilepsy Stewart et al. (2016) ToM 3 Clinical 55 −1.03 (−1.33,
−0.72)
Hedges’ g N/R Low risk
Controls 125
Idiopathic generalised epilepsy Stewart et al. (2016) ToM 2 Clinical 62 −0.59 (−0.87,
−0.31)
Hedges’ g N/R Low risk
Controls 104
Temporal lobe epilepsy Bora and Meletti
(2016)
FER 16 Clinical 580 −0.87 (−1.05,
−0.69)
Cohen’s d 46.55% Low risk
Controls 425
ToM 11 Clinical 569 −0.86 (−1.07,
−0.64)
Cohen’s d 49.95% Low risk
Controls 353
(continued on next page)
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4.3. Strengths and limitations
This is the ﬁrst review to our knowledge to examine social cognition
across such a broad range of clinical disorders. As a result, we con-
centrated on facial emotion recognition and ToM, which have been the
overwhelming focus of research in this ﬁeld to date. Currently, ToM
tasks are typically grouped together, though these include a relatively
heterogeneous array of measures, requiring participants to make
inferences regarding sarcasm, hints, faux pas and/or complex aﬀective
states (for example see Baron-Cohen et al., 2001; Corcoran et al., 1995;
Gregory et al., 2002). In future, diﬀerentiation of tasks assessing cog-
nitive and aﬀective components of ToM may provide greater sensitivity
to domain-speciﬁc impairments. Similarly, though ‘global’ scores in-
dicated a deﬁcit among clinical groups in the identiﬁcation of facial
emotions, there was variation in the emotion-speciﬁc patterns of deﬁ-
cits among the diﬀerent clinical conditions. A greater understanding of
Table 1 (continued)
Condition Reference Domains
assessed
Studies
included
Sample n Eﬀect size
(95% CI)
Eﬀect size
metric
Heterogeneity (I2) Publication bias
Huntington’s disease Bora et al. (2016b) FERa 18 Clinical 413 −1.33 (−1.52,
−1.14)
Cohen’s d N/R Possible risk
Controls 446
ToM 12 Clinical 238 −1.72 (−2.09,
−1.35)
Cohen’s d 70% Low risk
Controls 199
Mild cognitive impairment Bora and Yener
(2017)
FER 13 Clinical 370 −0.58 (−0.73,
−0.43)
Cohen’s d 0% Low risk
Controls 434
ToM 6 Clinical 143 −0.63 (−0.91,
−0.35)
Cohen’s d 34% Low risk
Controls 259
Multiple sclerosis Cotter et al. (2016) FER 13 Clinical 473 −0.64 (−0.81,
−0.47)
Hedges’ g 36% Low risk
Controls 423
ToM 12 Clinical 429 −0.71 (−0.88,
−0.55)
Hedges’ g 23% Low risk
Controls 345
Parkinson’s disease Gray and Tickle-
Degnen (2010)
FER 28 Clinical 1110 −0.41 (−0.64,
−0.19)
Hedges’ g N/R Low risk
Controls
Bora et al. (2015b) ToM 18 Clinical 487 −0.83 (−1.09,
−0.57)
Cohen’s d N/R Low risk
Controls 459
Traumatic brain injury Babbage et al. (2011) FER 13 Clinical 296 −1.11 (−1.25,
−0.97)
Hedges’ g N/R Low risk
Controls 296
Developmental disorders
Attention deﬁcit hyperactivity
disorder
Bora and Pantelis
(2016)
FER 25 Clinical 1021 −0.44 (−0.59,
−0.30)
Cohen’s d N/R Low risk
Controls 764
ToM 24 Clinical 1010 −0.45 (−0.62,
−0.29)
Cohen’s d N/R Low risk
Controls 1024
Autism spectrum disorder Chung et al. (2014) ToM 11 Clinical 264 −0.81 (−1.14,
−0.48)
Hedges’ g N/R Possible risk
Controls 243
Intellectual disability Yirmiya et al. (1998) ToM 17 Clinical N/R −0.45 (−0.61,
−0.29)
Cohen’s d N/R N/R
Controls N/R
Speciﬁc language impairment
(children)
Nilsson and de López
(2016)
ToM 17 Clinical 329 −0.98 (−1.23,
−0.74)
Cohen’s d 55.23% Low risk
Controls 416
Abbreviations: CI: Conﬁdence Interval; FER: Facial emotion recognition; N/R: Not reported; ToM: Theory of Mind.
a Negative emotions subscale score; comprising total score for anger, disgust, sadness and fear facial aﬀect recognition tasks only.
Fig. 2. Facial emotion recognition eﬀect size estimates and corresponding 95% conﬁdence intervals across clinical conditions relative to healthy controls.
*95% CI data not available.
**Negative emotions subscale score, comprising total score for anger, disgust, sadness and fear facial aﬀect recognition tasks only.
Abbreviations: ADHD: Attention deﬁcit hyperactivity disorder; ALS: Amyotrophic lateral sclerosis; ARMS: At-risk mental state; BD: Bipolar disorder; BPD: Borderline personality
disorder; BVFTD: Behavioural variant frontotemporal dementia; FEP: First-episode psychosis; GAD: Generalised anxiety disorder; MCI: Mild cognitive impairment; MDD: Major depressive
disorder; MS: Multiple sclerosis; OCD: Obsessive-compulsive disorder; PD: Panic disorder; PTSD: Post-traumatic stress disorder; SP: Social phobia; SUD: Substance use disorder (non-
alcohol); TBI: Traumatic brain injury.
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these condition-speciﬁc emotion recognition proﬁles could provide
further insight into underlying disease pathology. For example, the
recognition of fear and sadness has been reported to be strongly asso-
ciated with the integrity of medial temporal lobe structures, whereas
disgust is more closely associated with the insular cortex, though there
is evidence of considerable overlap across emotions (Adolphs, 2002).
There are also other aspects of social cognition which have received
comparatively little attention. Vocal tasks, for example, are potentially
more sensitive than faces for identifying emotion recognition deﬁcits in
Parkinson’s disease (Gray and Tickle-Degnen, 2010), and can also be
used to assess emotion recognition among individuals with visual im-
pairments. Bodily aﬀect recognition is also an emerging area of interest
across disorders, providing an additional approach for social cognitive
assessment (Cecchetto et al., 2014; Vaskinn et al., 2016).
Though many of the original research studies matched the clinical
and control groups for various demographic characteristics (such as
age, sex and level of education), this was inconsistently reported across
the included meta-analyses and may have inﬂuenced their results.
Variation in the clinical and demographic samples of the included
studies, as well as the range of social cognitive assessments that were
used, are likely to have contributed to the statistical heterogeneity that
was observed among many of the eﬀect size estimates. Comorbidities
are also common across many of these disorders and could be con-
sidered as a potential confounder. For example, depression is common
among people with psychiatric and neurological diagnoses (Fusar-Poli
et al., 2014; Siegert and Abernethy, 2005; Ulfvebrand et al., 2015), and
may have inﬂuenced emotional processing. However, a number of
studies included in the meta-analyses explicitly excluded individuals
with major depressive disorder or else reported no association between
the severity of depressive symptoms with social cognitive task perfor-
mance, suggesting social cognitive deﬁcits were not secondary to de-
pressive comorbidity (e.g. Cotter et al., 2016; Daros et al., 2013; Gray
and Tickle-Degnen, 2010). The impact of other common comorbid
neuropsychiatric symptoms such as apathy and anxiety on social cog-
nitive performance is less well understood, though the results presented
in this review suggest the latter is unlikely to be a major causal factor
for social cognitive decline.
The majority of the meta-analyses included in this review included a
large number of studies and participants, providing robust eﬀect size
estimates. However, given this is an emerging ﬁeld, several of the
epilepsy, PTSD, anxiety and eating disorder estimates were based on a
limited pool of original research studies and should be interpreted with
caution. Similarly, tests for evidence of publication bias associated with
each of the eﬀect size estimates indicated a low risk of publication bias
across the majority of the meta-analyses included in this review.
However, some of the meta-analyses included a relatively small number
of studies (< 10 for each estimate), and are therefore likely to be un-
derpowered to detect evidence of potential publication bias (Higgins
and Green, 2011). Many of the meta-analyses also performed meta-re-
gression analyses to examine potential clinical, cognitive and demo-
graphic moderators of these eﬀect sizes. However, these meta-regres-
sion analyses would have been underpowered to detect anything but
very large study-level eﬀects since, in many cases, they would include
only aggregate data from a relatively small number of studies. We
therefore did not include the results of these moderator analyses in the
current review.
4.4. Future opportunities in social cognitive research
Impairments in social and occupational functioning and reduced
quality of life are common across a wide range of psychiatric, devel-
opmental and neurological disorders. There is emerging evidence that
social cognitive dysfunction may contribute to such diﬃculties
(Aydemir et al., 2013; Bishop-Fitzpatrick et al., 2017; Cotter et al.,
2017; Fett et al., 2011; Phillips et al., 2011; Trevisan and Birmingham,
2016). In addition to ongoing psychiatric or neurological symptoms,
misperception of others emotional or mental states coupled with diﬃ-
culties in empathising during social situations may play a causal role in
the breakdown of interpersonal relationships (Couture et al., 2006).
Though these links would beneﬁt from further (particularly long-
itudinal) investigation, social cognitive dysfunction does represent a
potentially modiﬁable risk factor for these diﬃculties (Penton-Voak
et al., 2017). Assessment and treatment of social cognitive dysfunction
may also oﬀer wider treatment beneﬁts. For example, recent evidence
suggests that cognitive training aimed at treating facial emotion re-
cognition biases exhibited by individuals with low mood can also help
to alleviate their depressive symptoms (Iacoviello et al., 2014; Penton-
Voak et al., 2012).
Despite the evidence that social cognitive dysfunction is common
among individuals with a range of medical conditions, targeted treat-
ments for these deﬁcits remain in their relative infancy. The most
widely researched pharmacological agent for the treatment of social
cognitive impairment has been oxytocin, a neuropeptide hormone
thought to play a key role in social behaviours (Meyer-Lindenberg et al.,
Fig. 3. Theory of mind eﬀect size estimates and corresponding 95% conﬁdence intervals across clinical conditions relative to healthy controls.
*95% CI data not available
Abbreviations: ADHD: Attention deﬁcit hyperactivity disorder; ALS: Amyotrophic lateral sclerosis; ARMS: At-risk mental state; ASD: Autism spectrum disorder; BD: Bipolar disorder;
BPD: Borderline personality disorder; BVFTD: Behavioural variant frontotemporal dementia; FEP: First-episode psychosis; IG: Idiopathic generalised epilepsy; MCI: Mild cognitive
impairment; MDD: Major depressive disorder; MS: Multiple sclerosis; OCD: Obsessive-compulsive disorder.
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2011). Despite some promising trials conducted in patients with psy-
chotic, aﬀective and autism spectrum disorders (Mercedes Perez-
Rodriguez et al., 2015; Preti et al., 2014), its beneﬁts appear incon-
sistent across studies and methodologically problematic (Bradley and
Woolley, 2017; Leppanen et al., 2017). At present, more eﬀective ap-
proaches have involved the use of social cognitive remediation, though
these also appear to oﬀer only modest beneﬁts (García-Casal et al.,
2017; Kurtz et al., 2016).
An important limitation in this area is the poor or unknown psy-
chometric properties of many social cognitive tests, though eﬀorts are
currently underway to establish how these measures compare (Pinkham
et al., 2016). Improved characterisation and operationalization of social
cognition and other ‘hot’ cognitive processes are necessary to facilitate
and advance treatment eﬀorts. There are currently a wide range of
measures in use (Henry et al., 2015), which also makes direct com-
parisons between studies diﬃcult. In an eﬀort to combat this, test
batteries such as EMOTICOM are currently under development, pro-
viding comprehensive computerised assessments for social cognitive
and cognitive-aﬀective processes that can be used across both healthy
individuals and clinical populations (Bland et al., 2016).
4.5. Conclusion
Social cognitive deﬁcits appear to be a core cognitive phenotype of
many developmental, neurological and psychiatric disorders. There is a
need to raise awareness of the importance of these diﬃculties among
clinicians, researchers and patients alongside the more established as-
pects of cognition that may be negatively aﬀected, such as attention and
memory. Future studies should seek to address the ‘real world’ im-
plications of these deﬁcits and to develop eﬀective transdiagnostic in-
terventions for those individuals that are adversely aﬀected.
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